RankingsPricing
  1. US-listed companies
  2. AYTU BIOPHARMA, INC

AYTU BIOPHARMA, INCAYTU

Market cap
$13.75M
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Aug 31,
2013		Jun 30,
2015		Jun 30,
2016		Jun 30,
2017		Jun 30,
2018		Jun 30,
2019		Jun 30,
2020		Jun 30,
2021		Jun 30,
2022		Jun 30,
2023
Net loss--------58-110-17
Depreciation, amortization and accretion-118,202874,78943369109
Impairment expense--812---756
Inventory write-down-------722
Stock-based compensation expense-1902,9463348,51511456
Gain on derivative warrant liability---12,572212,8094-9,830,5501,830-05
Gain from contingent consideration--------21
Amortization of senior debt (premium) discount--------0-01
Issuance of Stock for Milestone Payments--------1-
Gain on debt extinguishment---------0-
Other noncash adjustments-------000
Accounts receivable-157,0585,369355,03150,74314-2-77
Inventory-39,442485,265-195,42726,752101,0967-3-14
Prepaid expenses and other current assets---------21
Accounts payable and other-547,314------3-82
Accrued liabilities----414,570-596,654961,85841-134
Other operating assets and liabilities, net-------0-00
Net cash used in operating activities-37,704----15,940,322-13,831,377-28,373,887-26-29-5
Contingent consideration payment----7,385505,025202,688130
Other investing activities--------000
Net cash used in investing activities-26,870----484,292-1,061,985-5,655,772-3-3-0
Net proceeds from issuance of stock207,462-8739,857---45-16
Payment made to fixed payment arrangement-------644
Proceeds from (Repayments of) Lines of Credit----------2
Payments made to borrowings-------55160
Proceeds from borrowings-------5115-
Payment for debt issuance costs--298,322-----10
Other financing activities--------0-0-
Net cash provided by financing activities352,122---2319713029
Net change in cash and cash equivalents-------2-314
Cash paid for interest------1134
Other noncash investing and financing activities--------00